Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Robert Califf Back as FDA Head

    Cancer Discovery
    |April 4, 2022
    PubMed
    Summary
    This summary is machine-generated.

    Robert Califf, MD, returns as FDA commissioner. His previous tenure included establishing the Oncology Center of Excellence and expanding real-world evidence use in regulatory decisions.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same journal

    DNA, Peptide Vaccines Advance Against GBM.

    Cancer discovery·2026
    Same journal

    AKR1C1 Promotes ADC Resistance by Altering Uptake and Export.

    Cancer discovery·2026
    Same journal

    Acquisition of Centromeric Features Supports Telomere Integrity.

    Cancer discovery·2026
    Same journal

    Germline CDK12 variants in aggressive prostate cancer.

    Cancer discovery·2026
    Same journal

    Type II JAK2 Inhibitor Gets Off to a Strong Start.

    Cancer discovery·2026
    Same journal

    Pancreatic Cancer: Translating Tumor Biology into Actionability.

    Cancer discovery·2026
    See all related articles

    Area of Science:

    • Regulatory Science
    • Public Health Policy
    • Oncology Drug Approval

    Background:

    • Robert Califf, MD, has been confirmed by the U.S. Senate to return as the head of the Food and Drug Administration (FDA).
    • Dr. Califf's prior leadership at the FDA was marked by significant initiatives.
    • These initiatives included the establishment of the Oncology Center of Excellence and efforts to broaden the use of real-world evidence (RWE).

    Purpose of the Study:

    • To highlight the return of Robert Califf, MD, to lead the FDA.
    • To summarize key accomplishments during his previous term.
    • To underscore the impact of his leadership on regulatory processes.

    Main Methods:

    • Review of public records and Senate confirmation proceedings.
    • Analysis of FDA initiatives during Dr. Califf's previous tenure.

    Related Experiment Videos

  • Identification of key policy shifts and center establishments.

    • Main Results:

    • Dr. Califf's return to the FDA leadership position has been confirmed.
    • His previous term was characterized by the creation of the Oncology Center of Excellence.
    • Significant efforts were made to integrate real-world evidence into the FDA's decision-making framework.

    Conclusions:

    • Dr. Califf's reappointment signifies a continuation of his established policy directions.
    • His leadership is expected to further advance the use of real-world evidence in drug and device regulation.
    • The Oncology Center of Excellence is poised for continued development under his guidance.